# Sebacia

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sebacia

- Industry: Medical Devices & Equipment
- Headquarters: Duluth, US
- Website: www.sebacia.com
- Total disclosed funding: $58M
- Latest round: Series D (Jul 25, 2017)
- Investors on record: 5

## About

Sebacia, Inc. is a company focused on advanced dermatological solutions, specializing in innovative laser-based treatments designed to effectively target and eliminate acne lesions for patients.Founded in 2010 and headquartered in Duluth, US, Sebacia, Inc. specializes in laser-based dermatological treatments. The company has successfully completed 10 deals, with its most recent funding round occurring on August 30, 2019. In this round, Sebacia raised USD 10 mn in Series E funding, bringing its total amount raised to USD 10 mn and current valuation to USD 69.44 mn. The CEO, Anthony Lando, leads the company in its endeavors within the dermatological sector.Sebacia.com specializes in advanced dermatological solutions, primarily focusing on the development and distribution of its innovative laser-based treatment for acne. Their core product is designed to target and eliminate acne lesions through a unique combination of laser technology and specialized topicals, aiming to provide effective, long-lasting results for patients suffering from persistent acne. The treatment is utilized by dermatologists and skincare professionals, facilitating access to a broad client base that includes both individual patients and clinical partners. The company’s offerings have been strategically launched in key markets across North America and Europe, addressing the growing demand for effective skincare solutions in urban populations where acne is prevalent. Sebacia.com aims to enhance the quality of life for end users by providing a safe and effective alternative to traditional acne therapies.Sebacia.com generates revenue primarily through direct business-to-business transactions with dermatology clinics and skincare providers, who purchase their laser systems and accompanying products. The revenue model is based on a structured pricing plan that includes upfront costs for the laser devices, followed by a recurring revenue stream from consumable components necessary for ongoing treatments. These consumables are essential to the functionality of the laser system, ensuring that clinics can provide continuous care to their patients. The firm also explores strategic partnerships with healthcare providers to expand its market reach and enhance service offerings, solidifying its presence in the competitive dermatological landscape. The combination of direct sales and partnerships allows Sebacia.com to optimize its revenue potential while maintaining strong relationships with its client base.Sebacia, Inc. plans to utilize its recent Series E funding of USD 10 mn, raised on August 30, 2019, to support the development and launch of new products aimed at enhancing its treatment offerings. The company is targeting expansion into additional markets in North America and Europe, with specific attention to urban areas experiencing high demand for acne treatment solutions. These initiatives aim to be implemented within the next few years, allowing Sebacia to solidify its market presence and cater to a broader audience.

## Funding rounds

- Series D, Jul 25, 2017, $20M — Domain Associates, Versant Ventures, Accuitive Medical Ventures, Salem Partners, Mass General Brigham Ventures
- Series C, May 21, 2015, $8M — Domain Associates, Versant Ventures, Accuitive Medical Ventures
- Series B, May 30, 2014, $11M — Domain Associates, Versant Ventures, Accuitive Medical Ventures
- Series B, Jun 27, 2013, $6.5M — Domain Associates, Versant Ventures, Accuitive Medical Ventures
- Series B, Mar 29, 2012, $6.5M — Domain Associates, Versant Ventures, Accuitive Medical Ventures
- Series A, May 20, 2011, $5.6M — Domain Associates, Versant Ventures, Accuitive Medical Ventures

## Investors

- Domain Associates (https://capitalatlas.ai/funds/domain-associates) — Series A, Series B, Series C, Series D
- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series A, Series B, Series C, Series D
- Accuitive Medical Ventures (https://capitalatlas.ai/funds/accuitive-medical-ventures) — Series A, Series B, Series C, Series D
- Salem Partners — Series D
- Mass General Brigham Ventures (https://capitalatlas.ai/funds/mass-general-brigham-ventures) — Series D